In a nutshell:

The report “An innovative approach to R&D for neglected patients, Ten years of experience & lessons learned by DNDi” provides facts & figures about the model of DNDi, after 10 years of R&D.

- Partnerships in 43 countries, over 350 collaborations, namely with 20 pharmaceutical and biotechnology companies and with over 50 universities and research institutes.
- DNDi expenses from 2003-2013: EUR 182.5 million => to deliver 6 improved treatments and develop 12 new chemical entities (NCEs) in DNDi’s pipeline
- Out of the expenses, EUR 138 million dedicated to Research and Development:
  - EUR 51 million for Research stage (screening, hit-to-lead, lead optimisation)
  - EUR 33 million for Translation stage (pre-clinical, clinical Phase I and Phase II/proof-of-concept)
  - EUR 31 million for Development stage (clinical Phase IIb/III, registration)
  - EUR 23 million for Implementation stage (access)

5 case studies of treatments developed by DNDi and partners:

The new report offers case studies of three treatments delivered and two new chemical entities in development by DNDi, including total monetary costs but excluding in-kind contributions from many partners and attrition rates for drugs still in development:

1. ASAQ: artesunate-amodiaquine fixed-dose combination for deadly malaria
   - Cost of DNDi’s R&D: a total of EUR 12 million
   - Objective: develop and monitor implementation of a fixed-dose combination therapy for malaria
   - Timeline: began development in 2003 and was delivered in 2007
   - Impact: over 250 million treatments distributed by Sanofi throughout Africa (31 countries) since its launch in 2007.

2. NECT: nifurtimox-eflornithine combination therapy for sleeping sickness
   - Cost of DNDi’s R&D: a total of EUR 6.8 million
   - Objective: develop an improvement over previous therapies, some of them being highly toxic (arsenic-based)
   - Timeline: began development in 2003 and was delivered in 2009
• Impact: the first new treatment option in 25 years for sleeping sickness (human African trypanosomiasis). Today, 96% of all late-stage patients are treated with NECT, replacing melarsoprol, a toxic, arsenic-based drug that killed 1 in 20 patients. Over 13,000 treatments distributed.

3. SSG&PM: sodium stibogluconate and paromomycin new combination therapy for visceral leishmaniasis in Africa
   • Cost of DNDi’s R&D: a total of EUR 11.5 million
   • Objective: develop an improved, short-course therapy (monotherapy length being 30 days of infusions)
   • Timeline: began development in 2004 and was delivered in 2010
   • Impact: Since 2010, 23,000 patients in East Africa have been treated with SSG&PM.

4. Fexinidazole, a new drug candidate (new chemical entity) for sleeping sickness
   • Cost of DNDi’s R&D: an estimated cost of EUR 26.5 million for development and registration
   • Objective: develop an oral treatment to replace the current combination therapy (NECT), that include infusions twice a day/7 days
   • Timeline: began development in 2005 and currently in Phase II/III clinical trials. Estimated to be delivered by 2016
   • Impact: potential impact is to treat all the patients, even in the most remote areas, with pills, in their village.

5. Oxaborole SCYX-7158, the first new chemical entity developed specifically for sleeping sickness,
   • Cost of DNDi’s R&D: an estimated cost of EUR 38.3 million for development and registration
   • Objective: develop an oral treatment with a single pill to replace the current combination therapy (NECT), that include infusions twice a day/7 days
   • Timeline: began development in 2003 and currently in a Phase I clinical trial. Estimated to be delivered by 2018
   • Impact: potential impact is to treat all the patients, even in the most remote areas, with a single pill, in their village

Media contacts:
Violaine Dällenbach: vdallenbach@dndi.org / Tel: +41 22 906 92 47 / Mobile: +41 79 424 14 74
Samantha Bolton: samanthabolton@gmail.com / Mobile: +41 79 239 23 66
Oliver Yun: e-mail: oyun@dndi.org / Mobile: +1-646-266-5216